Chartwell Retirement Residences

BioGX and Bosch Healthcare Solutions | May 27, 2020

BioGX and Bosch Healthcare Solutions have partnered to develop point-of-care infectious disease tests for the Bosch Vivalytic all-in-one platform. Vivalytic is a universal sample-to-result platform for molecular diagnostics which can be used at the point-of-need. The patient sample is placed into the test cartridge, which is then inserted into the Vivalytic analyzer. Since the cartridge already contains all the necessary reagents, the test can be conducted with full automation and a faster turna...

Future of Healthcare,Medical Devices

Capterra | November 30, 2022

The rising adoption of connected medical devices is accelerating cyberattacks, according to Capterra’s new Medical IoT Survey of healthcare IT professionals. The survey also reveals that 67% of healthcare cyberattacks impact patient data and nearly half impact patient care, an indication that rising security risks in the industry are leading to severe consequences in patient outcomes and privacy. The medical internet of things is helping to make healthcare more convenient, eff...

Net Health | September 17, 2020

Net Health announced today that it is expanding its employee health electronic documentation solution, Agility®, by adding a new dashboarding capability to help hospital executives track and monitor key performance indicators for employee health. Business Insights for Employee Health is a new module that is being offered as part of the comprehensive Agility solution, which tracks compliance and employee wellness for healthcare organizations....

Medical Devices

GeneQuantum Healthcare | May 16, 2022

GeneQuantum Healthcare Co., Ltd. a global innovative biotechnology company dedicated to the development of bioconjugate drugs, announced that two of the company's bioconjugate drug candidates have won the approval for clinical trials in Australia, further enhancing GeneQuantum's pipelines in the clinical stage. They are GQ1005, an ADC with an excellent bystander killing effect, and GQ1007, a first-in-class antibody-immune-agonist-conjugateboth with global intellectual property r...